No Data
No Data
GoodRx Holdings (NASDAQ:GDRX) Has A Rock Solid Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart
BofA Securities Maintains GoodRx(GDRX.US) With Sell Rating, Maintains Target Price $5
BofA Securities analyst Allen Lutz maintains $GoodRx(GDRX.US)$ with a sell rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 49.1% and a
GoodRx Holdings Underperform Rating: Concerns Over Biosimilar Affordability and Generic Reimbursement Market Dynamics
GoodRx Offers Exclusive Discount to Biosimilar Targeting AbbVie's Humira
GoodRx Partners With Boehringer Ingelheim to Discount Humira Biosimilar
Express News | GoodRx: Initiative to Provide Citrate-Free Adalimumab-Adbm, Boehringer’s Biosimilar to Humira, at Low Cash Price Exclusively on GoodRx
No Data
Tan Chin Seng klang : must buy more apples and Nvidia